triiodothyronine has been researched along with Adrenal Cortex Neoplasms in 1 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitotane-treated patients with ACC showed low FT4, normal FT3 and TSH and impaired TSH response to TRH, characteristic of central hypothyroidism." | 7.83 | Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. ( Cannavò, S; Cotta, OR; Frasca, F; Gullo, D; Pellegriti, G; Russo, M; Scollo, C; Squatrito, S, 2016) |
| "Mitotane-treated patients with ACC showed low FT4, normal FT3 and TSH and impaired TSH response to TRH, characteristic of central hypothyroidism." | 3.83 | Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. ( Cannavò, S; Cotta, OR; Frasca, F; Gullo, D; Pellegriti, G; Russo, M; Scollo, C; Squatrito, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russo, M | 1 |
| Scollo, C | 1 |
| Pellegriti, G | 1 |
| Cotta, OR | 1 |
| Squatrito, S | 1 |
| Frasca, F | 1 |
| Cannavò, S | 1 |
| Gullo, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma[NCT05344027] | 35 participants (Actual) | Observational | 2022-04-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for triiodothyronine and Adrenal Cortex Neoplasms
| Article | Year |
|---|---|
Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.
Topics: Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Female; Humans; Hypothyroidi | 2016 |